DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the AARTI PHARMALABS LIMITED (AARTIPHARM) share price today?

AARTI PHARMALABS LIMITED (AARTIPHARM) is trading at ₹707.9 on the NSE, down 1.32% on the day. Source: DocStoX.

What is the PE ratio of AARTI PHARMALABS LIMITED?

AARTI PHARMALABS LIMITED has a price-to-earnings (PE) ratio of 36.7 in the Healthcare sector.

What is the market capitalisation of AARTI PHARMALABS LIMITED?

AARTI PHARMALABS LIMITED has a market capitalisation of approximately ₹6,409 crore.

AARTI PHARMALABS LIMITED

AARTIPHARM·NSE·Healthcare

₹707.90▼ -9.50 (-1.32%)

Healthcare · Pharmaceuticals

Revenue under pressure recently

Day₹698.05

₹720.00

52W₹585

₹97032%

Open

₹717.40

High

₹720.00

Low

₹698.05

Prev Close

₹717.40

Volume

1.03L

VWAP

₹707.38

Snapshot

Key fundamentals

Market Cap

₹6,409 Cr

P/E Ratio

36.74Expensive

P/B Ratio

2.98

EPS

₹19.27

Book Value

₹234.00

ROE

8.59%Average

ROCE

11.00%Decent

Dividend Yield

0.21%

Debt / Equity

0.35Moderate

Face Value

₹5.00

52W High

₹969.50

52W Low

₹585.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatMedium uncertainty

Fair value estimate

₹243

▼ 65.7%downside

Trading at ₹708 — 66% above our estimate

BearFair valueBull

₹207₹243₹319

/100

Business quality — Watch the fundamentals

Growth 0Profitability 30Efficiency 8Valuation 58

Plain English

Our view

Revenue under pressure recently
Low debt relative to equity
Revenue has been shrinking

Strengths

Low debt relative to equity

Risks

Revenue has been shrinking
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

9% ROE fading to 13% over ~3 yrs, on ₹234 book

₹222

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹319

Analyst target

No analyst coverage

—

Blended fair value₹243

What the numbers say

Investment thesis

Bull case

Low debt relative to equity

Bear case

Revenue has been shrinking
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

36.7Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

8.6%Average

Above 15% is considered healthy for Indian equities

ROCE

11.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.35Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹6,409 Cr

P/B

2.98

EPS

₹19.27

Div Yield

0.21%

What changed

Recent changes

Foreign investors-0.2% stake last quarter
Domestic institutions-0.2% stake last quarter
Promoters-0.22% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 36.7×

Growth

Shrinking

-2% rev CAGR

Profitability

Modest

8.6% ROE

Financial health

Comfortable

D/E 0.35

Momentum

N/A

No technicals

Today

Trading activity

Delivery %44.8%

Turnover₹727.97L Cr

Trades13,674

VWAP₹707.38

Face value₹5.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-2.2%

—

10Y

—

Profit

-3.2%

—

10Y

—

EPS

-3.4%

—

10Y

—

Profile

Cons

Stock is trading at 3.03 times its book value
Company has a low return on equity of 11.9% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Promoters trimmed their stake by 0.22 pts; foreign investors sold 0.22 pts; domestic institutions reduced 0.18 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

43%

Promoter

Promoters

42.9%-0.22

Public

41.7%+0.64

FII / FPI

8.2%-0.22

DII

7.2%-0.18

Quarterly trend

Ownership over time

Q1 FY27

Promoter42.86%

FII8.17%

DII7.22%

Public41.74%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]